As a Second-line Treatment for Metastatic Gastric Adenocarcinoma Patients, the Safety and Effective of Vactosertib Administration in Combination With Paclitaxel+Ramucirumab is Evaluated, and a Phase 2a Clinical Trial to Biomarkers

NCT04656002 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer

Interventions

DRUG: Vactosertib

Sponsor

Samsung Medical Center